Simvastatin ointment, a new treatment for skin inflammatory conditions

Journal of Dermatological Science

Volumn 66, Issue 2, 2012, Pages 127-135

  Adami, Marina ^a   Prudente, Arthur da Silveira ^a   Mendes, Daniel Augusto Gasparin Bueno ^a   Horinouchi, Cintia Delai da Silva ^a   Cabrini, Daniela Almeida ^a   Otuki, Michel Fleith ^b  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

Author keywords

Ear oedema; Epidermis hyperproliferation; Ointment; Simvastatin; Skin inflammation

Indexed keywords

ACETONE; CYCLINE; DEXAMETHASONE ACETATE; MYELOPEROXIDASE; PHORBOL 13 ACETATE 12 MYRISTATE; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; EAR DISEASE; EAR EDEMA; EAR THICKNESS; EDEMA; ENZYME ACTIVITY; EPIDERMIS; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE MIGRATION; MEDICAL PARAMETERS; MOUSE; NONHUMAN; OINTMENT; PRIORITY JOURNAL; SKIN INFLAMMATION;

ACUTE DISEASE; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DERMATITIS, IRRITANT; DISEASE MODELS, ANIMAL; FEMALE; MICE; OINTMENTS; PEROXIDASE; PROLIFERATING CELL NUCLEAR ANTIGEN; SIMVASTATIN; TETRADECANOYLPHORBOL ACETATE;

EID: 84859779121     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.02.015     Document Type: Article

References (29)

1. Nezic L., Skrbic R., Dobric S., Stojiljkovic M.P., Jacevic V., Satara S.S., et al. Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation. Basic Clin Pharmacol Toxicol 2009, 104:185-191.
2. Veillard N.R., Mach F. Statins: the new aspirin?. Cell Mol Life Sci 2002, 59:1771-1786.
3. Namazi M.R. Statins: novel additions to the dermatologic arsenal?. Exp Dermatol 2004, 13:337-339.
4. Nezic L., Skrbic R., Dobric S., Stojiljkovic M.P., Satara S.S., Milovanovic Z.A., et al. Effect of simvastatin on proinflammatory cytokines production during lipopolysaccharide-induced inflammation in rats. Gen Physiol Biophys 2009, 28. Spec No: 119-126.
5. Pruefer D., Makowski J., Schnell M., Buerke U., Dahm M., Oelert H., et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 2002, 106:2104-2110.
6. Otuki M.F., Pietrovski E.F., Cabrini D.A. Topical simvastatin: preclinical evidence for a treatment of skin inflammatory conditions. J Dermatol Sci 2006, 44:45-47.
7. Stanley P.L., Steiner S., Havens M., Tramposch K.M. Mouse skin inflammation induced by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate. Skin Pharmacol 1991, 4:262-271.
8. Suzuki K., Ota H., Sasagawa S., Sakatani T., Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 1983, 132:345-352.
9. De Young L.M., Kheifets J.B., Ballaron S.J., Young J.M. Edema and cell infiltration in the phorbol ester-treated mouse ear are temporally separate and can be differentially modulated by pharmacologic agents. Agents Actions 1989, 26:335-341.
10. Pietrovski E.F., Paludo K.S., Mendes D.A., Guimaraes F.de.S., Veiga S.S., Buchi Dde F., et al. B1 and B2 kinin receptor participation in hyperproliferative and inflammatory skin processes in mice. J Dermatol Sci 2011, 64:23-30.
11. Gábor M. Ear inflammation models and their pharmacological applications 2000, Akadémiai Kiadó, Budapest.
12. Rao T.S., Currie J.L., Shaffer A.F., Isakson P.C. Comparative evaluation of arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation. Inflammation 1993, 17:723-741.
13. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982, 78:206-209.
14. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008, 11:81s-110s.
15. Ajuebor M.N., Singh A., Wallace J.L. Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol 2000, 279:G238-G244.
16. Tramposch K.M., Zusi F.C., Marathe S.A., Stanley P.L., Nair X., Steiner S.A., et al. Biochemical and pharmacological properties of a new topical anti-inflammatory compound, 9-phenylnonanohydroxamic acid (BMY 30094). Agents Actions 1990, 30:443-450.
17. Iarovinskii B.G., Zurochka A.V., Ebert L., Shtivel'band M.I., Popov G.K. Status of the regulatory function of neutrophils in patients with atopic dermatitis. Biull Eksp Biol Med 1995, 120:318-319.
18. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 2002, 59:990-997.
19. Diomede L., Albani D., Sottocorno M., Donati M.B., Bianchi M., Fruscella P., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001, 21:1327-1332.
20. Proksch E., Brandner J.M., Jensen J.M. The skin: an indispensable barrier. Exp Dermatol 2008, 17:1063-1072.
21. Gambichler T., Bischoff S., Bechara F.G., Altmeyer P., Kreuter A. Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders. J Dermatol Sci 2008, 49:125-132.
22. Feingold K.R., Man M.Q., Proksch E., Menon G.K., Brown B.E., Elias P.M. The lovastatin-treated rodent: a new model of barrier disruption and epidermal hyperplasia. J Invest Dermatol 1991, 96:201-209.
23. Proksch E., Holleran W.M., Menon G.K., Elias P.M., Feingold K.R. Barrier function regulates epidermal lipid and DNA synthesis. Br J Dermatol 1993, 128:473-482.
24. Wood L.C., Jackson S.M., Elias P.M., Grunfeld C., Feingold K.R. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 1992, 90:482-487.
25. Mao-Qiang M., Feingold K.R., Elias P.M. Inhibition of cholesterol and sphingolipid synthesis causes paradoxical effects on permeability barrier homeostasis. J Invest Dermatol 1993, 101:185-190.
26. Grubauer G., Elias P.M., Feingold K.R. Transepidermal water loss: the signal for recovery of barrier structure and function. J Lipid Res 1989, 30:323-333.
27. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002, 23:482-486.
28. Honari S. Topical therapies and antimicrobials in the management of burn wounds. Crit Care Nurs Clin North Am 2004, 16:1-11.
29. Lynde C. Moisturizers for the treatment of inflammatory skin conditions. J Drugs Dermatol 2008, 7:1038-1043.